CY1112632T1 - Αναστολεις ασπαρτυλ πρωτεασης - Google Patents

Αναστολεις ασπαρτυλ πρωτεασης

Info

Publication number
CY1112632T1
CY1112632T1 CY20121100182T CY121100182T CY1112632T1 CY 1112632 T1 CY1112632 T1 CY 1112632T1 CY 20121100182 T CY20121100182 T CY 20121100182T CY 121100182 T CY121100182 T CY 121100182T CY 1112632 T1 CY1112632 T1 CY 1112632T1
Authority
CY
Cyprus
Prior art keywords
hiv
relates
compounds
aspartyl
activity
Prior art date
Application number
CY20121100182T
Other languages
English (en)
Inventor
Michael Robin Hale
Roger Tung
Stephen Price
Robin David Wilkes
Wayne Carl Schairer
Ashley Nicholas Jarvis
Andrew Spaltenstein
Eric Steven Furfine
Vicente Samano
Istvan Kaldor
John Franklin Miller
Michael Stephen Brieger
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of CY1112632T1 publication Critical patent/CY1112632T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Η παρούσα εφεύρεση αφορά νέα κατηγορία σουλφοναμιδίων που είναι αναστολείς ασπαρτύλ πρωτεάσης. Σε μία πραγματοποίηση, αυτή η εφεύρεση αφορά σε νέα κατηγορία αναστολέων Ασπαρτύλ πρωτεάσης HIV που χαρακτηρίζονται από ειδική σύνταξη και φυσικοχημικά χαρακτηριστικά. Αυτή η εφεύρεση επίσης αφορά σε φαρμακευτικές συνθέσεις που περιλαμβάνουν αυτές τις ενώσεις. Οι ενώσεις και οι φαρμακευτικές συνθέσεις αυτής της εφεύρεσης είναι ιδιαιτέρως κατάλληλες για αναστολή δραστικότητας πρωτεάσης ΗΙV-1 και ΗΙV-2 και επομένως μπορεί να χρησιμοποιηθούν ως αντι-ιικοί παράγοντες έναντι των ΗΙV-1 και ΗIV-2 ιών. Αυτή η εφεύρεση επίσης αφορά σε μεθόδους για αναστολή της δραστικότητας ασπαρτύλ πρωτεάσης ΗIV χρησιμοποιώντας τις ενώσεις αυτής της εφεύρεσης και μεθόδους για διαλογή ενώσεων για αντι-ΗIV δραστικότητα.
CY20121100182T 1999-06-11 2012-02-22 Αναστολεις ασπαρτυλ πρωτεασης CY1112632T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13907099P 1999-06-11 1999-06-11
US19021100P 2000-03-17 2000-03-17
EP06009072A EP1686113B1 (en) 1999-06-11 2000-06-08 Inhibitors of aspartyl protease

Publications (1)

Publication Number Publication Date
CY1112632T1 true CY1112632T1 (el) 2016-02-10

Family

ID=26836833

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100182T CY1112632T1 (el) 1999-06-11 2012-02-22 Αναστολεις ασπαρτυλ πρωτεασης

Country Status (31)

Country Link
EP (2) EP1194404B1 (el)
JP (2) JP4503896B2 (el)
KR (1) KR100762188B1 (el)
CN (2) CN101245058A (el)
AR (1) AR031520A1 (el)
AT (2) ATE534622T1 (el)
AU (1) AU779994B2 (el)
BR (1) BR0011745A (el)
CA (1) CA2380858C (el)
CO (1) CO5160337A1 (el)
CY (1) CY1112632T1 (el)
CZ (1) CZ303052B6 (el)
DE (1) DE60027722T2 (el)
DK (2) DK1194404T3 (el)
ES (2) ES2263478T3 (el)
HK (1) HK1046899B (el)
HU (1) HUP0300385A3 (el)
IL (3) IL146918A0 (el)
MX (1) MXPA01012808A (el)
MY (1) MY137777A (el)
NO (1) NO323951B1 (el)
NZ (1) NZ516003A (el)
PE (1) PE20010230A1 (el)
PL (1) PL210227B1 (el)
PT (2) PT1686113E (el)
SI (1) SI1194404T1 (el)
TN (1) TNSN00129A1 (el)
TR (3) TR200200407T2 (el)
TW (3) TWI318116B (el)
WO (1) WO2000076961A1 (el)
ZA (1) ZA200110177B (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1086076B1 (en) * 1998-06-19 2004-12-22 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
CZ304273B6 (cs) 2001-02-14 2014-02-12 Tibotec Pharmaceuticals Ltd. 2-(Substitovaná-amino)benzothiazolsulfonamidová sloučenina, způsob její přípravy a farmaceutická kompozice s jejím obsahem
US7285566B2 (en) * 2002-01-07 2007-10-23 Erickson John W Resistance-repellent retroviral protease inhibitors
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
MXPA04010527A (es) * 2002-04-26 2004-12-13 Gilead Sciences Inc Acumulacion celular de analogos de fosfonato de los compuestos inhibidores de la proteasa del virus de inmunodeficiencia humana (vih).
US6632816B1 (en) * 2002-12-23 2003-10-14 Pharmacor Inc. Aromatic derivatives as HIV aspartyl protease inhibitors
WO2005000249A2 (en) * 2003-06-27 2005-01-06 Smithkline Beecham Corporation Preparation of chemical compounds
EP1658276B1 (en) 2003-08-18 2012-10-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
MXPA06006730A (es) * 2003-12-15 2006-08-31 Schering Corp Inhibidores de aspartil proteasa heterociclicos.
CN1953964A (zh) 2004-03-11 2007-04-25 塞阔伊亚药品公司 抗耐药性反转录病毒蛋白酶抑制剂
TWI383975B (zh) 2004-03-31 2013-02-01 Tibotec Pharm Ltd 製備（３Ｒ，３ａＳ，６ａＲ）六氫-呋喃并〔２，３-ｂ〕呋喃-３-醇之方法
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
EP1855672A4 (en) * 2005-03-11 2011-11-30 Glaxosmithkline Llc HIV PROTEASE INHIBITORS
CA2632095A1 (en) 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
US20080070910A1 (en) * 2006-07-24 2008-03-20 Desai Manoj C Therapeutic compounds and methods
PL2089371T3 (pl) 2006-11-09 2011-06-30 Janssen Sciences Ireland Uc Sposoby wytwarzania heksahydrofuro[2,3-b]furan-3-olu
US9808527B2 (en) * 2006-11-21 2017-11-07 Purdue Research Foundation Methods and compositions for treating HIV infections
DK2152667T3 (da) 2007-04-27 2011-05-16 Tibotec Pharm Ltd Fremgangsmåder til fremstilling af N-isobutyl-n-(2-hydroxy-3-amin-4-phenylbutyl)-p-nitrobenzenesulfonylamid-derivater
GB2452952A (en) * 2007-09-20 2009-03-25 Npil Pharmaceuticals N-[2-Hydroxy-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-sulphonamide derivatives via N-[2-oxo-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-imine skeleton
US8592487B2 (en) 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
KR101811314B1 (ko) * 2009-09-22 2017-12-26 얀센 알 앤드 디 아일랜드 Ｈｉｖ 감염의 치료 및 예방
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
CN103193570B (zh) * 2013-04-09 2014-01-22 湖北来凤腾升香料化工有限公司 一种羟基高选择性保护方法
US20170253607A1 (en) * 2014-09-11 2017-09-07 Shionogi & Co., Ltd. Long-acting hiv protease inhibitor
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3635907A1 (de) * 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
US5475013A (en) * 1990-11-19 1995-12-12 Monsanto Company Retroviral protease inhibitors
EP0558603B1 (en) * 1990-11-19 1998-08-26 Monsanto Company Retroviral protease inhibitors
US5843946A (en) * 1992-08-25 1998-12-01 G.D. Searle & Co. α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
ES2196436T3 (es) * 1992-10-30 2003-12-16 Searle & Co Acidos sulfonilalcanoilamino-hidroxietilamino-sulfamicos utiles como inhibidores de proteasas retrovirales.
ATE174587T1 (de) * 1993-08-24 1999-01-15 Searle & Co Hydroxyaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
EP1586558A3 (en) * 1995-01-20 2005-10-26 G.D. Searle LLC. Bis-sulfonamide hydroxyethylamino retroviral protease inhinitors
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
RU2174519C2 (ru) * 1995-03-10 2001-10-10 Джи. Ди. Сирл Энд Ко. Гидроксиэтиламино сульфонамиды гетероциклокарбонил аминокислоты, ингибирующие ретровирусную протеазу
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
WO1997018205A1 (en) * 1995-11-15 1997-05-22 G.D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
GB9712504D0 (en) * 1997-06-17 1997-08-20 Dundee Teaching Hospitals Nhs Thermal imaging method and apparatus
WO1999010373A1 (en) * 1997-08-26 1999-03-04 Wisconsin Alumni Research Foundation Non-immunosuppressive cyclosporins and their use in the prevention and treatment of hiv infection
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion

Also Published As

Publication number Publication date
CZ20014431A3 (cs) 2002-06-12
TR200200407T2 (tr) 2002-08-21
TR200603871T2 (tr) 2007-01-22
DK1686113T3 (da) 2012-02-20
NO20016034L (no) 2002-01-18
PL352830A1 (en) 2003-09-08
AU5600600A (en) 2001-01-02
DE60027722D1 (en) 2006-06-08
IL202633A0 (en) 2010-06-30
EP1194404B1 (en) 2006-05-03
ES2263478T3 (es) 2006-12-16
TW200425891A (en) 2004-12-01
EP1194404A1 (en) 2002-04-10
DK1194404T3 (da) 2006-09-04
TW200804252A (en) 2008-01-16
CA2380858A1 (en) 2000-12-21
PE20010230A1 (es) 2001-03-15
CN101245058A (zh) 2008-08-20
SI1194404T1 (sl) 2006-10-31
TWI299000B (en) 2008-07-21
TW593248B (en) 2004-06-21
EP1686113A1 (en) 2006-08-02
HK1046899B (zh) 2007-03-02
ATE325091T1 (de) 2006-06-15
PL210227B1 (pl) 2011-12-30
ATE534622T1 (de) 2011-12-15
CN1361765A (zh) 2002-07-31
IL146918A0 (en) 2002-08-14
IL202633A (en) 2013-02-28
IL146918A (en) 2010-06-16
HUP0300385A3 (en) 2007-05-29
AR031520A1 (es) 2003-09-24
ES2375823T3 (es) 2012-03-06
MY137777A (en) 2009-03-31
WO2000076961A1 (en) 2000-12-21
NO20016034D0 (no) 2001-12-10
NO323951B1 (no) 2007-07-23
AU779994B2 (en) 2005-02-24
TR200202528T2 (tr) 2003-02-21
TNSN00129A1 (fr) 2005-11-10
CZ303052B6 (cs) 2012-03-14
JP4503896B2 (ja) 2010-07-14
ZA200110177B (en) 2003-01-13
TWI318116B (en) 2009-12-11
CO5160337A1 (es) 2002-05-30
PT1686113E (pt) 2012-02-20
KR100762188B1 (ko) 2007-10-04
BR0011745A (pt) 2002-03-19
CN100516034C (zh) 2009-07-22
MXPA01012808A (es) 2002-07-22
HK1046899A1 (en) 2003-01-30
EP1686113B1 (en) 2011-11-23
JP2009046493A (ja) 2009-03-05
DE60027722T2 (de) 2007-04-26
KR20020033642A (ko) 2002-05-07
NZ516003A (en) 2004-02-27
HUP0300385A2 (hu) 2003-07-28
CA2380858C (en) 2011-12-06
JP2003502309A (ja) 2003-01-21
PT1194404E (pt) 2006-08-31

Similar Documents

Publication Publication Date Title
CY1112632T1 (el) Αναστολεις ασπαρτυλ πρωτεασης
AP1717A (en) Sulfonamide inhibitors of aspartyl protease.
MXPA03010538A (es) Nuevas formulaciones que inhiben la proteasa aspartilo.
MY115797A (en) Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
EA199700331A1 (ru) Тгф-содержащие сульфонамидные ингибиторы аспартил-протеазы
MX9603909A (es) Derivados de sulfonamida como inhibidores de proteasa aspartilo.
CY1107460T1 (el) Αντι-ιικα παραγωγα αζαινδολης
ATE311391T1 (de) Aspartyl-protease-inhibitoren
CY1112267T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης ns3-σερινης του ιου ηπατιτιδας c
KR950702960A (ko) 레트로바이러스 프로테아제 저해제로서 유용한 히드록시에틸아미노 술폰아미드(hydroxyethylamino sulfonamides useful as retroviral protease inhibitors)
PT1052250E (pt) Inibidores de protease retroviral sulfonilalcanoilamino hidroxietilamino sulfonamidas
CA2195125A1 (en) Difluorostatone antiviral agents
EA200500533A1 (ru) Пептидные производные - ингибиторы слияния при вич-инфекции
MY135869A (en) Inhibitors of aspartyl protease
MX9708057A (es) Sulfonamidas que contienen thf inhibidoras de la aspartilproteasa.
NO963254L (no) Makrocykliske difluorstatonderivater som er anvendbare som antivirale midler
ITPD20040151A1 (it) Inibitori peptidomimetici di proteasi retrovirali e loro uso come antivirali